ervogastat
systemic, oral DGAT2 inhibitor Ph. II for NASH with fibrosis opt. of liver-targeting candidate PF-06427878 J. Med. Chem., 02 November 2022 Pfizer, Cambridge, MA and Groton, CT
Molecules of the Month - November 2022
Molecules of the Month
- ervogastat
- PTC258
- sirpiglenastat
- ENT-01
- mobocertinib
- compound 29
- compound 27 (CTPS1)
- compound 14d
- TDI-11861
- EG-011